The global biotechnology market is projected to surpass $1.55 trillion in 2024 thanks to innovations in gene editing, AI-driven drug discovery, and novel therapeutic approaches. This momentum has been further bolstered by recent pro-business policies introduced by President-elect Donald Trump that are aimed at fostering domestic innovation and reducing barriers for emerging biotech firms.
The Trump administration’s latest proposed initiatives have included expanded tax incentives for research and development, streamlined regulatory frameworks, and increased funding for public-private partnerships in healthcare.
